Cyclacel
Pharmaceuticals, Inc. CYCC,
today announced that effective July 11, 2011, Cyclacel Limited, a wholly-owned
subsidiary of the Company, entered into an amendment of its license agreement,
dated September 10, 2003 between Cyclacel Limited and Daiichi Sankyo Company,
Limited relating to certain rights which Cyclacel Limited
has licensed from Daiichi Sankyo with regard to the Company's sapacitabine
drug.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in